Pluri Inc.

NASDAQ:PLUR

$0.7402 USD

-$0.04 (-5.1%)

Volume
75.34K
Average Volume
102.44K
Market Capitalization
$30.7M
P/E Ratio
-1.63
Dividend Yield
0.00%
Price Target
$
Year High
$1.11
Year Low
$0.43
Payout Ratio
$0.00
Current Ratio
$0.00

Industry, Sector & symbol

Stock Exchange NASDAQ Global Market
CEO Mr. Yaacov Yanay
Industry Biotechnology
Sector Healthcare
Current Symbol PLUR
CUSIP 72942G104
CIK 0001158780
Web https://pluri-biotech.com/
Phone 972 7 4710 8600
Currency USD
Employees 123
Country IL

Liquidity

Debt-to-Equity Ratio 1.38
Payout Ratio 0.00
Current Ratio 0.00
Quick Ratio 0.00
Cash Ratio 0.00

Sales & Book Value

Annual Sales $287K
Price / Sales 86.00
Cash Flow -0.36
Price / Cash Flow -2.04
Price / Book 6.95

Price Target and Rating

Average Stock Price Forecast $
High Stock Price Forecast $
Low Stock Price Forecast $
Forecast Upside/Downside %
Consensus Rating Neutral
Rating Score(0-5) 3
Research Coverage 0 Analysts

Profitability

EPS (Most Recent Fiscal Year) $-0.77
Trailing P/E Ratio -1.63
PEG Ratio -0.04
P/E Growth -0.04
Net Income $-28.32M
Net Margin -5265.55%
Pretax Margin -5344.26%
Return on Equity -164.47%
Return on Assets 0.00%

Financials Score

AltmanZ Score
Piotroski Score 4.00
Working Capital -4.53M
Total Assets -
Ebit -35.48M
Market Cap 30.7M
Total Liabilities 34.95M

Poll Results

About Pluri Inc. (NASDAQ:PLUR) Stock

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly k ... nown as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Pluri to Present and Participate in Upcoming Conferences

2022-10-31 08:00:00

HAIFA, Israel, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”)(formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today announced its participation in three upcoming conferences.

Pluristem (PSTI) Phase III Study Misses Goal, Stock Down

2022-07-14 12:24:04

Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

2022-07-13 09:59:02

Pluristem Therapeutics Inc (NASDAQ: PSTI) announced topline results from its Phase 3 study of intramuscular administration of allogeneic PLX-PAD cells for muscle injury following arthroplasty for hip fracture.  The 240-subject study did not meet the primary endpoint, the Short.

Best Penny Stocks to Buy as January Ends? 4 to Watch

2022-01-22 11:30:00

Here are four penny stocks to add to your end of January watchlist The post Best Penny Stocks to Buy as January Ends? 4 to Watch appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 For Your List in January

2022-01-10 10:38:56

Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Frequently Asked Questions

What is the current Pluri Inc. (PLUR) stock price?

Pluri Inc.(NASDAQ:PLUR) stock price is $0.7402 in the last trading session. During the trading session, PLUR stock reached the peak price of $1.11 while $0.43 was the lowest point it dropped to. The percentage change in PLUR stock occurred in the recent session was --5.1% while the dollar amount for the price change in PLUR stock was -$-0.04.

PLUR's industry and sector of operation?

The NASDAQ listed PLUR is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of PLUR?

Ms. Efrat Livne-Hadass | Vice President of Human Resources
Mr. Yaacov Yanay | President, Chief Executive Officer & Director
Ms. Chen Franco-Yehuda | Chief Financial Officer, Treasurer & Secretary
Mr. Lior Raviv | Chief Technology Officer
Dr. Nitsan Halevy M.D. | Chief Medical Officer

How many employees does PLUR have?

Number of PLUR employees currently stands at 123. PLUR operates from Building No. 5, Haifa, None 3508409, IL.

Link for PLUR official website?

Official Website of PLUR is: https://pluri-biotech.com/

How do I contact PLUR?

PLUR could be contacted at phone #972 7 4710 8600 and can also be accessed through its website. PLUR operates from Building No. 5, Haifa, None 3508409, IL.

How many shares of PLUR are traded daily?

The average number of PLUR shares traded daily for last 3 months was 102.44K.

What is the market cap of PLUR currently?

The market value of PLUR currently stands at $30.7M with its latest stock price at $0.7402